Cargando…

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

BACKGROUND: Therapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies. However, as most patients still fail to respond, approaches to augment immunotherapeutic efficacy are needed. Here, we investigated the ability of histone deacetylase 6 (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laino, Andressa S., Betts, B. C., Veerapathran, A., Dolgalev, I., Sarnaik, A., Quayle, S. N., Jones, S. S., Weber, J. S., Woods, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366050/ https://www.ncbi.nlm.nih.gov/pubmed/30728070 http://dx.doi.org/10.1186/s40425-019-0517-0

Ejemplares similares

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
por: North, Brian J., et al.
Publicado: (2017)

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
por: Laino, Andressa S, et al.
Publicado: (2020)

Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
por: Liu, Jiaqi, et al.
Publicado: (2016)

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
por: Yoshida, Tatsuya, et al.
Publicado: (2020)

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
por: Huang, Pengyu, et al.
Publicado: (2016)

Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
por: Peng, Xiaopeng, et al.
Publicado: (2023)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis
por: Balliu, Manjola, et al.
Publicado: (2015)

Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
por: Zhou, Bingyi, et al.
Publicado: (2021)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
por: Traoré, Mohamed D. M., et al.
Publicado: (2017)

Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine
por: Cosenza, Maria, et al.
Publicado: (2017)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Developing potent PROTACs tools for selective degradation of HDAC6 protein
por: An, Zixuan, et al.
Publicado: (2019)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

HDAC inhibitors enhance the immunotherapy response of melanoma cells
por: Booth, Laurence, et al.
Publicado: (2017)

The Role of HDAC6 in Cancer
por: Aldana-Masangkay, Grace I., et al.
Publicado: (2011)

HDAC6 and Ovarian Cancer
por: Haakenson, Joshua, et al.
Publicado: (2013)

Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma
por: Pal, Harish C., et al.
Publicado: (2015)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

HDAC6 regulates IL-17 expression in T lymphocytes: implications for HDAC6-targeted therapies
por: Yan, Bing, et al.
Publicado: (2017)

Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
por: Jo, Hyein, et al.
Publicado: (2022)

A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors
por: Goracci, Laura, et al.
Publicado: (2016)

Correction to: Developing potent PROTACs tools for selective degradation of HDAC6 protein
por: An, Zixuan, et al.
Publicado: (2019)

Efficacy of intralesional injection with PV-10 in combination with co-inhibitory blockade in a murine model of melanoma
por: Pilon-Thomas, Shari, et al.
Publicado: (2014)

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
por: Wang, Wenshi, et al.
Publicado: (2012)

HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma
por: Souri, Zahra, et al.
Publicado: (2020)

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma
por: Garrett, Matthew C., et al.
Publicado: (2023)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

HDAC2 Is Involved in the Regulation of BRN3A in Melanocytes and Melanoma
por: Heppt, Markus V., et al.
Publicado: (2022)

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
por: Sriramareddy, Sathya Neelature, et al.
Publicado: (2022)

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival
por: Levidou, Georgia, et al.
Publicado: (2021)

HDAC6 in Diseases of Cognition and of Neurons
por: LoPresti, Patrizia
Publicado: (2020)

HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
por: Putcha, Preeti, et al.
Publicado: (2015)

The Importance of the “Time Factor” for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors
por: Cellupica, Edoardo, et al.
Publicado: (2023)

HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model
por: Maharaj, Kamira, et al.
Publicado: (2020)

Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites
por: Engel, Jessica A., et al.
Publicado: (2015)

Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
por: Putcha, Preeti, et al.
Publicado: (2017)

Inhibition of HDAC6 Activity Protects Against Endothelial Dysfunction and Atherogenesis in vivo: A Role for HDAC6 Neddylation
por: Nomura, Yohei, et al.
Publicado: (2021)

Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer
por: Toomey, Paul, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uto1jnr18ilastk7ej59d023l6